Small molecule compound-based method to induce new bone formation and prevent per

Information

  • Research Project
  • 7325955
  • ApplicationId
    7325955
  • Core Project Number
    R43DE018583
  • Full Project Number
    1R43DE018583-01
  • Serial Number
    18583
  • FOA Number
    PA-06-20
  • Sub Project Id
  • Project Start Date
    8/1/2007 - 16 years ago
  • Project End Date
    2/28/2008 - 16 years ago
  • Program Officer Name
    WILLIAMS, JOHN
  • Budget Start Date
    8/1/2007 - 16 years ago
  • Budget End Date
    2/28/2008 - 16 years ago
  • Fiscal Year
    2007
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/15/2007 - 16 years ago
Organizations

Small molecule compound-based method to induce new bone formation and prevent per

[unreadable] DESCRIPTION (provided by applicant): One of the most challenging problems in clinical Dentistry is the loss of alveolar bone. The primary causes of alveolar bone loss are periodontitis and tooth loss. There is also substantial evidence suggesting that there is a link between alveolar bone loss and osteoporosis, another common disease of the bone in which bone mineral density (BMD) is reduced and bone micro-architecture is disrupted. Nevertheless, current osteoporosis treatments have not been proven to be effective in treating periodontal bone loss. In fact, Bisphosphonates, a class of non-hormone bone-sparing drugs that are most prescribed in treating osteoporosis, have been linked to the development of osteonecrosis of the jaw (ONJ). The absence of effective treatment options for periodontal bone loss has encouraged the continued search for successful therapeutic approaches. Both human and mouse genetic evidence indicates that the Wnt co-receptor LRP5 has an important role in the regulation of bone remodeling. Dickkopf (Dkk), a family of naturally occurring antagonists of the Wnt signaling pathway, functions as a negative regulator for osteogenesis through binding to LRP5. Studies of a high bone mass (HBM) human kindred indicated that the HBM was caused by a LRP5 G171V mutation resulting in abolishing Dkk inhibition of Wnt signaling. The observation that no adverse phenotypes have been detected in humans with this LRP5 mutation, combined with the results from the animal studies with this LRP5 mutation, suggests that the interaction between LRP5 and Dkk can be a potential therapeutic target. In the preliminary studies, we have developed an innovative strategy that combines structural biology, computational screening and biological assays to identify compounds that could disrupt the interaction between Dkk and LRP5 and reverse Dkk-mediated inhibition of the Wnt signaling pathway. One lead compound (Enzo_D58) was shown to stimulate the osteogenic differentiation of cultured primary bone marrow stromal osteoblasts. Locally delivered Enzo_D58 effectively induced calvarial and alveolar new bone formation. In addition, orally administered Enzo_D58 was able to prevent alveolar bone loss in a rat periodontitis model. The oral bioactivity combined with the absence of any observable toxicity makes Enzo_D58 an attractive potential therapeutic agent for alveolar bone loss. In this proposed Phase I study we plan to further explore and validate the therapeutic potentials of the Dkk antagonistic compound Enzo_D58 for preventing alveolar bone loss in animal models. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH
  • Activity
    R43
  • Administering IC
    DE
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    121
  • Ed Inst. Type
  • Funding ICs
    NIDCR:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ENZO BIOCHEM, INC.
  • Organization Department
  • Organization DUNS
    081664328
  • Organization City
    FARMINGDALE
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    11735
  • Organization District
    UNITED STATES